Autolus Therapeutics (AUTL) Change in Account Payables (2018 - 2025)

Autolus Therapeutics (AUTL) has reported Change in Account Payables for 8 consecutive years, with -$7.5 million the latest figure, recorded in Q4 2025.

• Quarterly Change in Account Payables fell 2370.69% year-over-year to -$7.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (down 18.24% YoY) and the FY2025 annual result came in at $1.3 million, down 18.24% from the prior year.
• Change in Account Payables eased to -$7.5 million in Q4 2025 per AUTL's latest filing, from $5.4 million in the prior quarter.
• Over the last five years, Change in Account Payables for AUTL reached as high as $5.4 million in Q3 2025 and fell as low as -$7.5 million in Q4 2025.
• A 5-year average of $29350.0 and a median of $170500.0 in 2022 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables soared 7525.53% — and 2025, when it sank 2370.69%.
• Year by year, Change in Account Payables stood at -$1.0 million in 2021, then jumped by 110.55% to $109000.0 in 2022, then sank by 630.28% to -$578000.0 in 2023, then jumped by 157.27% to $331000.0 in 2024, then plunged by 2370.69% to -$7.5 million in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$7.5 million, $5.4 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.